secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001867096-24-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M
--------------------------------------------------------------------------------

- Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).
- Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).
- Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.
- Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.
- Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/0001867096-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000062/xers-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer